Inside the TERZO Phase 3 Trial of Duvelisib

Zinzani introduces the ongoing TERZO phase 3 trial as a logical next step built on the PRIMO results, describing it as a notably focused study. He explains that it is structured as a registration trial restricted to a single histologic subtype, the angioimmunoblastic and T-follicular helper category, reflecting the strength of the earlier subtype-specific data. Zinzani outlines the randomized design comparing duvelisib against investigator's choice of standard chemotherapy in patients who have received at least one prior line of systemic treatment, and reports encouraging accrual across participating European countries along with preliminary single-center experience consistent with PRIMO. Brammer emphasizes why the trial matters, noting that despite duvelisib's availability in the United States through an older label, regulators require randomized evidence of superiority over standard care to secure broad access. Both express hope that the study will ultimately demonstrate that benefit and potentially expand to additional regions.